ReviewGlobal health & medicine2019
Hepatocellular carcinoma with non-B and non-C hepatitis origin: epidemiology in Japan and surgical outcome.
Review in Global health & medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 11 citations in OpenAlex.
- Significant Decline in HCV-Related Mortality From Liver Cirrhosis and Chronic Liver Disease (2015-2022): A Sentinel Center Study.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
- First-Line Lenvatinib plus Pembrolizumab for Hepatocellular Carcinoma: Post hoc Analysis of Japanese Patients from the Phase 3 LEAP-002 Trial.Liver cancer · 2025Article
- Chronological changes in etiology, pathological and imaging findings in primary liver cancer from 2001 to 2020.Japanese journal of clinical oncology · 2025Article
- Characterization and Detection Strategy Exploration in Cryptogenic Hepatocellular Carcinoma: Insights From a Super-Aged Region in Japan.Cancer medicine · 2025Article
- Relationship between portal hypertension and liver stiffness measurements in the treatment of hepatocellular carcinoma from the surgeon's point of view in the Baveno VII era.Hepatobiliary surgery and nutrition · 2024Article
- Impact and usefulness of the transition to the new MAFLD classification for non-B, non-C HCC: a retrospective cohort study.BMC gastroenterology · 2023Article
- Clinical characteristics, prognosis, and surgical outcomes of patients with non-HBV and non-HCV related hepatocellular carcinoma: three-decade observational study.BMC gastroenterology · 2023Observational
- Prognostic Scores and Survival Rates by Etiology of Hepatocellular Carcinoma: A Review.Journal of clinical medicine research · 2023Review
- Non-B, Non-C Hepatocellular Carcinoma in an HBV- and HCV-Endemic Area: A Community-Based Prospective Longitudinal Study.Viruses · 2022Article
- Intended preoperative trans-arterial embolization for large hepatocellular carcinoma: a retrospective cohort study.World journal of surgical oncology · 2022Article
- Preoperative ALBI grade predicts the outcomes in non-B non-C HCC patients undergoing primary curative resection.BMC gastroenterology · 2021Article
- Comparative Immunohistochemical Analysis of Clinicopathological Subgroups in Hepatocellular Carcinomas from Japan and Indonesia.Journal of clinical and experimental hepatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During the last two decades, there has been a dramatic increase in so-called non-B non-C hepatocellular carcinoma (NBNC HCC) in Japan. Majority of NBNC HCC are considered as so-called metabolic HCC and some could be related to occult HBV infection. Although there have been some reports on histological features predominant in metabolic HCC, very few specific driver genes for NBNC HCC have been reported. Most of the NBNC HCC are found incidentally and are relatively large in size. Since liver function is generally normal or subnormal, such patients have a higher chance for undergoing curative surgery. Although there has been slightly conflicting long-term outcomes reported for NBNC HCC, slightly better outcomes may be expected compared to other etiologies after curative surgery. However, risk of recurrence depends on the background liver. NBNC HCC in cirrhotic patients have a persistently higher risk of tumor recurrence requiring a long-term postoperative surveillance. It would be safe to conclude at this moment that NBNC HCCs should be treated using the same surgical strategy as HCCs with viral origin, same operative indications and same follow-up protocol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.